Kronos Bio (NASDAQ:KRON) Stock Price Up 1.1%

Kronos Bio, Inc. (NASDAQ:KRON)’s stock price rose 1.1% on Wednesday . The stock traded as high as $1.00 and last traded at $0.96. Approximately 883,997 shares were traded during trading, an increase of 192% from the average daily volume of 302,912 shares. The stock had previously closed at $0.95.

Kronos Bio Stock Performance

The firm has a market cap of $60.10 million, a PE ratio of -0.51 and a beta of 1.82. The firm’s 50-day moving average price is $1.14 and its two-hundred day moving average price is $1.12.

Kronos Bio (NASDAQ:KRON) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.08. Kronos Bio had a negative net margin of 1,791.87% and a negative return on equity of 58.79%. The firm had revenue of $2.29 million during the quarter, compared to the consensus estimate of $1.50 million. As a group, sell-side analysts predict that Kronos Bio, Inc. will post -1.74 earnings per share for the current fiscal year.

Institutional Trading of Kronos Bio

Several institutional investors and hedge funds have recently bought and sold shares of the business. Cerity Partners LLC purchased a new stake in Kronos Bio in the 4th quarter valued at $513,000. Acuta Capital Partners LLC raised its position in Kronos Bio by 128.2% during the 3rd quarter. Acuta Capital Partners LLC now owns 718,739 shares of the company’s stock worth $934,000 after buying an additional 403,739 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Kronos Bio by 6.4% during the 3rd quarter. Acadian Asset Management LLC now owns 614,945 shares of the company’s stock worth $798,000 after buying an additional 36,909 shares during the last quarter. Hedge funds and other institutional investors own 64.09% of the company’s stock.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. The company's lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.